

# Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies

NCT06581887

---

**Status** RECRUITING  
**Sponsor** University College, London  
**Enrollment** 100 participants

## Key Eligibility Criteria

---

### Inclusion (16)

- DMD patients:
- Male
- Age range 7-17 years
- A genetically proven diagnosis of DMD.
- A genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-).

... and 11 more (see full listing online)

### Exclusion (19)

- DMD & BMD patients:
- Significant visual or hearing impairment
- Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study
- Current participation in a clinical trial investigating a new drug involved in dystrophin modulation.
- Inability to consent (for parents/guardians or self-reporting participants aged 16 and 17) or assent. This will exclude the rare individuals with extremely severe learning disability, as the assent in these patients is impossible (or the consent in self-reporting participants aged 16 and 17).

... and 14 more (see full listing online)

## Locations (1 total)

---

UCL GOS Institute of Child Health, London, United Kingdom